Located in the q32.1 region of human chromosome 1, the LEMD1 gene contains 9 exons, encoding multiple splice variants. At present, five transcript variants have been reported, with V1-3 mainly expressed in testis and colorectal cancer stem cells, while V4 and 5 are expressed at low levels in normal tissues (14). The LEMD1 protein belongs to the LEM domain protein family. The full-length protein consists of 181 amino acids with a molecular weight of ~20 kDa. It contains an N-terminal LEM domain and a C-terminal transmembrane region, making it a single-pass membrane protein (15,16) localized to the inner nuclear membrane, as presented in Fig. 1. The LEM domain is a conserved structure composed of ~40 amino acids that binds to the barrier-to-autointegration factor (BAF) (17). In classic LEM family proteins [such as lamina-associated polypeptide 2β (LAP2β), emerin and MAN1 (also known as LEMD3)], the LEM domain is located on the nucleoplasmic side and can anchor chromatin to the nuclear membrane by binding to BAF or BAF-DNA complexes (14,18). As a member of the aforementioned family, the LEMD1 protein is hypothesized to have similar structural features and interaction interfaces, potentially participating in nuclear membrane-chromatin connections (14,19,20).

Under normal physiological conditions, research on the normal biological functions of LEMD1 is limited due to its low expression levels in the majority of normal tissues. Previous studies suggest that LEMD1 may serve roles in cell cycle regulation, chromatin conformation maintenance and nuclear membrane homeostasis in specific cell types (such as germ cells) (15,21).

Typically, chromatin anchored to the nuclear periphery is associated with deacetylated histones, for example H3K9 and H3K27, and heterochromatin-associated markers (such as H3K9me2 and H3K9me3) (22), which maintains a relatively transcriptionally silent state (16). LEMD1 may anchor specific chromatin regions to the nuclear periphery through its LEM domain binding with BAF, potentially influencing the epigenetic state and transcriptional activity of these genes (16). Therefore, it is hypothesized that LEMD1 may participate in the regulation of gene expression. Other studies demonstrate potential associations between LEMD1 and gene splicing and epigenetic regulation processes (14,19,20,23). For example, a study by Li et al (11) suggests that the methylation state of the LEMD1 gene promoter region maintains high methylation in normal cells, resulting in silencing, while demethylation occurs in tumor cells leading to gene activation.

Additionally, during human spermatogenesis, LEMD1 transcripts are highly enriched in post-meiotic germ cells, with single-cell analyses showing maximal expression levels in late spermatids (24,25). This testis-specific pattern suggests a specialized role during spermatogenesis. Furthermore, as developing spermatids undergo chromatin remodeling and nuclear reshaping, a number of canonical nuclear envelope proteins (such as emerin and LEMD3) are absent; however, LEMD1 is one of the small number of LEM-domain factors expressed in these cells (24). Notably, LEMD1 is not detected at the nuclear periphery in spermatids but instead localizes within the nucleoplasm, and slowly localizes toward the posterior pole of the nucleus as spermatids elongate (24). This dynamic localization suggests that LEMD1 may help tether chromatin to the remaining nuclear scaffold or otherwise contribute to nucleus remodeling during the histone-to-protamine transition. Consistent with this hypothesis, in human spermiogenesis, LEMD1 (along with LAP2β and lamin B1) is suggested to substitute for the lamin B receptor (which is absent in spermatids) as an anchoring interface between chromatin and the nuclear envelope (26). As LEMD1 can bind to BAF, its presence in spermatids may possibly maintain transient chromatin-nuclear envelope connections at a stage when the lamina is being dismantled (24). These observations point to a physiological role for LEMD1 in orchestrating spermatid nuclear organization and stability, which may be critical for proper spermatogenesis and subsequent sperm function. These phenomena are consistent with the regulatory patterns of the majority of CTA genes, suggesting that LEMD1 has limited function in normal cell biology, while its abnormal expression primarily occurs in the context of tumorigenesis.

The present analyses using the Tumor Immune Estimation Resource 2.0 database (https://compbio.cn/timer2/) indicated that LEMD1 mRNA was highly expressed across ~20 types of cancer, whereas its expression level was low or undetectable in the majority of normal tissues, as illustrated in Fig. 2. In 2004, a study by Yuki et al (1) first reported a high expression of LEMD1 in colorectal cancer. Subsequently, in a study by Li et al (4), which analyses The Cancer Genome Atlas database and patient samples, reports that LEMD1 is notably upregulated in tissues and cell lines of gastric cancer compared with normal gastric mucosa and normal gastric epithelial cells. In addition to the digestive system, upregulated LEMD1 expression levels are reported in various solid tumors. For example, a study by Ghafouri-Fard et al (23) examines 30 prostate cancer cases and reports LEMD1 transcripts in 23% of them, while none are detected in 25 cases of benign prostatic hyperplasia. In OSCC, ~35% of patient tumors showed positive immunohistochemistry for LEMD1, with elevated LEMD1 protein expression levels in positive tumors (9). Both sequencing analysis and quantitative PCR validation of LEMD1 mRNA reveal notably increased transcription levels in papillary thyroid cancer tissues compared with adjacent normal thyroid tissues (27). Triple-negative breast cancer (TNBC), a type of breast cancer with a poor prognosis, reveals higher LEMD1 expression levels in tissues compared with other subtypes of breast cancer (11). Pancreatic cancer tissues also exhibit abnormally high LEMD1 expression levels, with reports indicating higher mRNA and protein levels compared with normal pancreatic tissues (2). Additionally, elevated LEMD1 expression levels are confirmed in non-small cell lung cancer (NSCLC) and are associated with malignant tumor behaviors. For example, higher LEMD1 levels are associated with poorer differentiation, advanced TNM stage and lymph node metastasis, and it predicts a shorter overall survival in patients with NSCLC (28). Furthermore, LEMD1 is also implicated in anaplastic large cell lymphoma (ALCL), with nucleophosmin-anaplastic lymphoma kinase/STAT3 signaling reported to upregulate LEMD1 expression levels (29). Overall, as a CTA, LEMD1 shows cancer tissue-specific high expression levels in multiple types of tumor, providing a basis for its potential use as a universal tumor marker.

Abnormal expression of LEMD1 not only has tumor specificity but is also notably associated with adverse clinicopathological features in multiple types of tumor, such as OSCC, thyroid cancer and TNBC (9,11,27), including more advanced TNM staging, lymph node metastasis, distant metastasis, increased tumor volume and vascular or lymphatic invasion (9,21,30). Previous studies suggest that in colorectal cancer, high expression of LEMD1 is positively correlated not only with lymph node metastasis and liver metastasis but also with tumor staging (1,14,21,31). A study by Sasahira et al (9) analyzed 289 patients with OSCC and found that LEMD1 expression levels were notably associated with tumor progression (T factor and clinical stage), nodal metastasis and poor prognosis. Furthermore, immunostaining for cytoplasmic LEMD1 is positive more frequently in patients with nodal metastasis compared with those without nodal metastasis [65.7% (46/70 patients) vs. 25.1% (55/219 patients)]. Multivariate analysis further identifies LEMD1 expression levels as an independent predictor of disease-free survival (DFS) in patients with OSCC (9). In patients with papillary thyroid cancer, high LEMD1 expression levels are also notably associated with a higher risk of lymph node metastasis (27). Additionally, in patients with TNBC, high LEMD1 expression levels are notably associated with a higher histological grade and shorter overall survival (OS) compared with those with low LEMD1 expression levels (11). A study on NSCLC reports that high LEMD1 expression levels are associated with later TNM staging, poorer tumor differentiation and an increased likelihood of lymph node metastasis, as well as increased cancer stem cell-like phenotypes and invasiveness (28). Additionally, a study by Cao et al (2) reports that LEMD1 is upregulated in pancreatic cancer tissue, and patients with high LEMD1 expression levels are more likely to develop distant metastasis, suggesting that LEMD1 may promote the metastatic ability of pancreatic cancer. These results indicate that high LEMD1 expression levels often suggest a more aggressive tumor biological behavior and worse clinical outcomes. By contrast, in normal tissues or benign/early stages of tumors, LEMD1 typically remains silent or at low levels, corresponding to an improved prognosis.

Due to the absence of LEMD1 in the majority of normal tissues and its abnormal appearance in tumors, its detection has potential value for tumor diagnosis and prognosis assessment. Multiple studies based on Kaplan-Meier survival analyses and multivariate Cox regression analyses report that LEMD1 can serve as an adverse prognostic factor for various types of tumor (9,11,21). In cohorts with colorectal or pancreatic cancer, patients with high LEMD1 expression levels have a notably reduced OS and DFS (2,32). A previous study on colorectal cancer constructed a three-gene model including LEMD1 to predict postoperative recurrence risk, with results showing that this model can effectively identify patients at high risk of recurrence (21). Several studies provide performance indicators for the diagnostic utility of LEMD1 (9,23,27). In papillary thyroid carcinoma, LEMD1 overexpression distinguishes tumor from normal tissue with high accuracy (receiver operating characteristic analysis yielding ~80% sensitivity and ~90% specificity) (27). Furthermore, in pancreatic cancer, an autoantibody biomarker panel incorporating LEMD1 achieved an area under the curve of 0.906 (93.3% sensitivity and 76.7% specificity) (33), highlighting the diagnostic potential of LEMD1 in oncology. Furthermore, as a CTA, LEMD1 also has potential immunogenicity that can be used for serological detection, such as the elevated LEMD1 autoantibodies detected in the blood of patients with pancreatic cancer (33), suggesting its research value in early diagnosis and recurrence monitoring. Whether similar anti-LEMD1 autoantibodies are present in other types of cancer is yet to be elucidated; however, given the status of LEMD1 as a CTA, this is a plausible possibility that warrants further investigation.

The survival analysis of the present review used the Gene Expression Profiling Interactive Analysis 2 (http://GEPIA2.cancer-pku.cn/) database and revealed that high LEMD1 expression levels were associated with a poor prognosis in colon, rectal, pancreatic and kidney cancer, as presented in Fig. 3. The aforementioned evidence suggests that detecting LEMD1 expression levels in tumor samples has the potential to provide useful prognostic information for clinical practice and guide subsequent treatment strategies.

Several functional experiments (2,4,9,21,27) reveal that LEMD1 promotes tumor progression in multiple types of cancer. For example, knocking down LEMD1 suppresses invasion and endothelial transmigration in OSCC; in gastric cancer, it promotes proliferation through effects on the cell cycle and apoptosis; in colorectal cancer, it enhances proliferation, migration, invasion and the epithelial-mesenchymal transition (EMT); and in thyroid and pancreatic cancer, gain- and loss-of-function experiments show effects on proliferation, migration/invasion and apoptosis (Table I) (2,4,10,11,21,27-31,34). A study by Li et al (4) demonstrates in gastric cancer cells that the overexpression of LEMD1 accelerates the G1/S phase transition and inhibits the expression of the apoptosis-related protein Bax, which increases tumor cell proliferation rates and promotes clone formation. By contrast, LEMD1 knockdown inhibits cell proliferation and induces cell cycle arrest and increases apoptosis. In vivo experiments also demonstrate that reduced LEMD1 levels slows the growth of transplanted tumors (4). In colon cancer, knockdown of LEMD1 notably reduces the proliferative activity of tumor cells (30). A study by Li and Zhang (28) on NSCLC cells reveals that upregulation of LEMD1 confers ‘stem cell-like’ phenotypes to tumors, including enhanced spherical clone formation and self-renewal capacity. A study by Cao et al (2) hypothesizes that LEMD1 knockdown notably enhances p53 pathway-mediated apoptosis. This finding suggests that, under normal conditions, LEMD1 helps restrain the pro-apoptotic activation of p53, likely by upregulating survival signals or pathways that keep p53 in check. Collectively, these studies indicate that LEMD1 promotes tumor cell proliferation and survival across multiple types of cancer, likely by facilitating cell-cycle progression and suppressing apoptosis, which contributes to tumor growth.

The presence of LEMD1 notably increases the invasive and metastatic potential of cancer cells. Previous studies suggest that LEMD1 is involved in metastatic progression in OSCC; high LEMD1 expression levels are associated with lymph node metastasis, and metastatic tumors have higher LEMD1 expression levels compared with non-metastatic tumors (9,10,34). In vitro functional experiments confirm that LEMD1 knockdown inhibits the invasive ability of oral cancer cells and reduces the ability of cancer cells to migrate through endothelial cell monolayers (9). Furthermore, in colorectal and pancreatic cancer models, LEMD1 silencing results in decreased tumor cell invasion and migration abilities, while overexpression made tumors more invasive (2,30). A study by Li et al (11) knocked down LEMD1 in TNBC cells, and the results reveal that these tumors not only reduced their in vitro migration ability but also reduced their tumorigenicity and metastatic ability in vivo. LEMD1 is also associated with the regulation of the EMT. For example, in thyroid cancer cells, LEMD1 overexpression decreases the levels of the epithelial marker E-cadherin and increases the expression of mesenchymal markers N-cadherin and Vimentin, promoting cells to acquire a spindle-shaped, migratory phenotype (27). Additionally, in OSCC (9) and TNBC, LEMD1 promotes transmembrane migration of vascular or lymphatic endothelial cells, enhancing metastatic capacity (11).

Therefore, evidence suggests that LEMD1 promotes the malignant phenotypes of tumors in multiple ways such as by accelerating cell proliferation and inhibiting apoptosis to promote tumor growth, while also enhancing cell migration and invasion characteristics to facilitate tumor metastasis. In summary, LEMD1 promotes metastasis by inducing the EMT and cytoskeletal reorganization (for example, via RhoA/ROCK signaling), which increases cancer cell motility and invasive capability.

LEMD1 can regulate multiple signaling pathways associated with tumor progression, including the PI3K/AKT, Wnt/β-catenin and RhoA/ROCK1 pathways, which exert tumor-promoting effects (4,21,27,30) (Fig. 4). The PI3K/Akt signaling pathway is important for regulating cell proliferation and survival, and LEMD1 is associated with the abnormal activation of this pathway in various tumors. For example, in gastric cancer research, overexpression of LEMD1 can promote the activation of the PI3K/Akt pathway and increase the phosphorylation levels of Akt (4). Additionally, silencing LEMD1 decreases p-PI3K and p-AKT, whereas LEMD1 overexpression increases p-PI3K and p-AKT (4). A study by Li et al (30) reports that the expression of LEMD1 is upregulated by the transcription factor SOX4, enhancing the activity of PI3K/Akt signaling and promoting the proliferation and invasion of colon cancer cells. Functional tests in NSCLC also show that LEMD1-mediated malignant phenotypes are reversed by the PI3K activator 740 Y-P, suggesting that the action of LEMD1 depends on the activation of the PI3K/Akt pathway (28). Taken together, these findings indicate that aberrant activation of the PI3K/Akt pathway is a possible primary downstream mechanism that mediates the tumor-promoting effects of LEMD1, as this pathway is consistently implicated in LEMD1-associated oncogenic processes across multiple types of cancer (4,28,30).

The Wnt/β-catenin pathway is also associated with LEMD1. Using gene set enrichment analyses on thyroid cancer, a study by Xu et al (27) reveals that the Wnt/β-catenin pathway is notably enriched in samples with high LEMD1 expression levels, downregulated E-cadherin and upregulated N-cadherin and Vimentin, suggesting the occurrence of the EMT. Further experiments confirm that knocking down LEMD1 reverses these changes, indicating that LEMD1 promotes proliferation and migration of thyroid cancer cells by activating the Wnt pathway to induce the EMT (27). Additionally, LEMD1 can influence the activity of the MAPK signaling pathway. In TNBC, LEMD1 overexpression leads to the excessive activation of the ERK1/2 pathway, while silencing LEMD1 reduces downstream ERK signal transduction, inhibiting tumor cell proliferation and migration (11). Furthermore, the interaction between LEMD1 and the p53/mTORC1 pathway is evident in pancreatic cancer, in which excessive LEMD1 can inhibit the function of the tumor suppressor protein p53 and activate mTORC1 signaling, promoting pancreatic cancer cell proliferation and metastasis (2). Although the precise mechanism is yet to be elucidated, LEMD1 activates pro-survival pathways upstream of p53, including the PI3K/Akt/mTOR pathway, which contributes to p53 inhibition and its reduced pro-apoptotic function. LEMD1 also affects cytoskeleton rearrangement-related pathways, such as the activation of RhoA/ROCK1 signaling, which promotes stress fiber formation and cell migration. A previous study investigating colorectal cancer shows that overexpression of LEMD1 can increase RhoA activity and enhance tumor cell migration, while interfering with LEMD1 has the opposite effect (21). In summary, LEMD1 may promote malignant tumor phenotypes through multi-target signaling pathway interactions, including but not limited to PI3K/Akt, Wnt/β-catenin, ERK/MAPK, p53/mTOR and RhoA/ROCK. Among these pathways the PI3K/Akt axis appears to be a central downstream node for the oncogenic effect of LEMD1, which supports its broad involvement in several types of cancer.

LEMD1 appears to activate different downstream signaling pathways depending on the type of tumor. For example, in colorectal cancer, SOX4-induced transcriptional upregulation of LEMD1 is linked to increased RhoA-GTP levels and enhanced cell migration via activation of the RhoA/ROCK signaling cascade (21). By contrast, in TNBC, LEMD1 overexpression downregulates ERK-inhibitory phosphatases such as dual specificity phosphatases 5 and 6, sustaining ERK/MAPK pathway activity, which in turn promotes tumor cell proliferation and the EMT (11). This tissue-specific signaling divergence may be attributed to differences in chromatin accessibility, transcription factor repertoires or regulatory cofactors. For example, in OSCC, particularly metastatic OSCC, the long non-coding (lnc)RNA LEMD1-antisense RNA 1 (AS1) stabilizes LEMD1 mRNA, which increases LEMD1 expression levels and activates the PI3K-AKT signaling pathway (34). Additionally, the expression of specific LEMD1 isoforms depending on the type of cancer, may influence partner protein interactions, therefore mediating distinct functional outcomes across tumor entities. These findings explain the extensive biological effects of LEMD1 and indicates a potential for further therapeutic interventions targeting associated pathways.

As a nuclear membrane-associated protein, LEMD1 may participate in tumorigenesis by influencing chromatin state and gene expression levels. Firstly, expression of LEMD1 is subject to epigenetic regulation. In normal cells, high methylation of the LEMD1 promoter leads to transcriptional silencing, while in tumors such as breast cancer, this promoter undergoes notable demethylation, resulting in abnormally high LEMD1 expression levels. This promoter demethylation positively correlates with poor patient prognosis (11), indicating that epigenetic activation of LEMD1 is linked to tumor progression. Additionally, the 1q32 region, where the LEMD1 gene is located, frequently undergoes copy number increases in certain types of cancer (such as breast, endometrial and ovarian clear cell carcinomas) (35-37), which may further enhance LEMD1 expression levels (38). Besides DNA methylation and gene amplification, transcription factors and non-coding RNAs also participate in the regulatory network of the expression of LEMD1. The SOX4 transcription factor can directly bind to the LEMD1 promoter and upregulate its transcription, thereby promoting the activation of the LEMD1/PI3K/Akt axis in colon cancer cells (30). In anaplastic lymphoma kinase fusion-positive ALCL, the oncogene nucleophosmin-ALK induces upregulation of microRNA (miR)-135b through the STAT3 pathway, and miR-135b is located in the first intron of the LEMD1 gene. With the upregulation of miR-135b, LEMD1 transcription is also co-activated (38). This reveals that inflammation-associated transcription factors or cytokine pathways (such as the IL-3/STAT3 pathway) can indirectly upregulate LEMD1 through miR-135b in ALCL, suggesting a mechanistic link between inflammatory signaling and LEMD1 expression levels.

Beyond ALCL, an associated inflammation linked mechanism is described in epithelial tumors. In NSCLC, LEMD1 intronic miR-135b enhances NF-κB signaling by repressing cylindromatosis tumor suppressor protein, which is a negative regulator of the NF-κB pathway, with the expression of miR-135b induced by IL-6/STAT3(39). As miR-135b resides within the first intron of LEMD1, these observations support a mechanistic connection between inflammatory cytokine pathways and the LEMD1 locus in solid tumors, potentially coupling IL-6/STAT3 input to NF-κB activation through an IL-6/STAT3 to miR-135b to NF-κB axis (39). This reveals that inflammatory/cytokine signaling can promote the expression of LEMD1 through epigenetic pathways. This connects stimulation of the tumor microenvironment with the expression of oncogenes.

Furthermore, lncRNAs also serve roles in regulating LEMD1. In OSCC, LEMD1-AS1 binds to LEMD1 mRNA, stabilizing its transcript level. This increases the LEMD1 expression levels and activates the PI3K/Akt pathway to promote tumor metastasis (34). Similarly, LINC00958 lncRNA indirectly enhances the expression of LEMD1 by absorbing miR-3064-5p (which can target and downregulate LEMD1). This enhances the malignant behavior of tumor cells (31). LEMD1-AS1, as a cuproptosis-related tumor suppressor, not only facilitates molecular subtyping and prognostic evaluation of ovarian cancer, but is also a potential biomarker for guiding personalized treatment strategies (40). These findings indicate that LEMD1 is involved in a complex gene regulatory network, with its expression levels subject to multi-level regulation including DNA methylation status, copy number variations, transcription factors (such as SOX4 and STAT3) and ncRNAs. These mechanisms not only determine the expression level of LEMD1 itself but may also influence the expression patterns of a number of downstream genes through LEMD1, which warrants additional in-depth research in the future.

In addition to LEMD1 expression levels, its location at the inner nuclear membrane suggests it may have direct effects on gene regulation. As with other LEM-domain proteins, LEMD1 may anchor chromatin to the nuclear periphery through interactions with BAF or the nuclear lamina, potentially silencing or activating specific gene regions (41). Although direct evidence is still lacking, such a mechanism may explain how LEMD1 influences a broad range of cellular behaviors. If LEMD1 tethers genomic regions associated with tumor suppressor genes or differentiation genes to the nuclear periphery, this may repress their expression levels, contributing to the maintenance of a proliferative, undifferentiated state in cancer cells. However, detachment of chromatin from the repressive nuclear periphery due to LEMD1 loss may activate tumor suppressor networks, which is consistent with observations of increased p53 pathway activity upon LEMD1 knockdown (2). These hypotheses require further validation, but they highlight that the pro-oncogenic effects of LEMD1 may stem from a combination of signaling pathway activation and higher-order genome organization changes.

Highly specific expression and tumor-promoting effects of LEMD1 in tumors make it an attractive therapeutic target. Traditional molecular targeting approaches may consider inhibiting the function (via small molecules) or expression [via small interfering (si)RNA and short hairpin RNA gene-silencing strategies] of LEMD1 to inhibit tumor progression. However, as LEMD1 is an intracellular nuclear envelope protein, designing small-molecule drugs that act on its transmembrane region or LEM domain is challenging. Gene-level interventions, such as via siRNA or antisense oligonucleotides, demonstrates notable antitumor effects in vivo (11). For example, in mouse models of TNBC, the silencing of LEMD1 inhibits tumor growth and metastasis (11), suggesting that therapies targeting LEMD1 may potentially reduce tumor malignancy. While monoclonal antibody or immunoconjugate approaches may be theoretically considered, the predominant inner nuclear membrane localization of LEMD1 prevents the accessibility of extracellular epitopes, rendering such strategies impractical for direct targeting.

A more feasible approach is the possible use of the classification of LEMD1 as a CTA for immunotherapeutic intervention (11). Under physiological conditions, LEMD1 expression levels are mostly restricted to immune-privileged germ cells, which minimizes central immune tolerance and potentially facilitates tumor-specific immune responses (3). Nevertheless, developing effective LEMD1-targeted immunotherapies poses several challenges. Firstly, intratumoral heterogeneity in LEMD1 expression levels presents a risk of immune escape through antigen downregulation, although this risk may be mitigated if LEMD1 is functionally indispensable for tumor cell survival. Secondly, for vaccine development, a critical prerequisite is the identification of immunogenic LEMD1-derived epitopes that can be presented by common HLA class I molecules (42). The robust activation of cytotoxic T lymphocytes against these epitopes would be essential to overcome any residual immune tolerances and mount effective tumor-specific immune responses. However, previous CTA-targeted cancer vaccines, such as recombinant melanoma-associated antigen A3 protein vaccines and New York esophageal squamous cell carcinoma-1 (NY-ESO-1) protein vaccines formulated with immune-stimulating complex matrix adjuvant, only had modest clinical efficacy, with objective response rates of ~13% in trials (43-46), highlighting the necessity for potent adjuvants or combination immunotherapies (such as immune checkpoint inhibitors) to enhance the antitumor immunity. Additionally, innovative delivery systems capable of targeting intracellular LEMD1 warrant further investigation. In terms of immunotherapy, LEMD1, as a CTA, is a possible target for tumor vaccines or T-cell therapies. Since expression of LEMD1 is limited in normal tissues (occurring mainly in the testis), immune responses against it would be tumor-specific and spare normal cells (21). It may be considered to use LEMD1 peptide vaccines to activate the T cells of patients, or to expand cytotoxic T lymphocytes that recognize LEMD1 ex vivo and reinfuse them to target LEMD1-positive tumors. Additionally, chimeric antigen receptor T-cell therapy may be adapted to recognize LEMD1-derived peptides presented on tumor cell MHC molecules, provided suitable epitopes and HLA restrictions are identified. Furthermore, advanced drug delivery systems could possibly be used to overcome the challenge of the intranuclear location (inner nuclear membrane) of LEMD1. For example, nanoparticle-based carriers or ligand-directed vehicles could potentially deliver LEMD1-targeted siRNA or protein-degrading agents specifically into tumor cells. In summary, LEMD1 has potential promising prospects as a therapeutic target, and these strategies (from CTA-targeted immunotherapies to gene silencing with innovative delivery mechanisms) warrant further investigation.

Tumor resistance is one of the key challenges affecting treatment efficacy, and increasing evidence suggests tumor-promoting genes such as LEMD1 serve a role in this process. LEMD1 enhances tumor cell tolerance to adverse environments by activating survival pathways such as PI3K/Akt and ERK, which may also include tolerance to stress induced by chemotherapeutic drugs. TNBC research reveals that knocking down LEMD1 not only inhibits tumor proliferation but also notably increases the sensitivity of tumor cells to paclitaxel chemotherapy (11). By contrast, TNBC cells with high LEMD1 expression levels are relatively resistant to paclitaxel, requiring higher drug doses to achieve the same inhibitory effect (11). This finding suggests that the presence of LEMD1 may confer a degree of chemotherapy resistance to tumor cells.

The mechanism of chemotherapy resistance may be associated with the antiapoptotic capacity that is promoted by LEMD1(4) chemotherapeutic drugs typically kill cancer cells by inducing DNA damage and apoptosis, while the inhibition of apoptosis by LEMD1 would reduce the effect of the drug. Additionally, the cancer cell stemness and the EMT state maintained by LEMD1 are also hypothesized to be associated with resistant phenotypes. Stem cell-like tumor cells often have an increased tolerance to radio- and chemotherapy, which may explain why LEMD1-enhanced stemness in NSCLC leads to more stubborn tumors that are difficult to eliminate (28). At the same time, the EMT process is often accompanied by increased chemotherapy resistance, and the LEMD1-induced EMT (27) may render tumor cells insensitive to certain drugs.

LEMD1 appears to mediate chemotherapy resistance through multiple, reinforcing mechanisms. One major mechanism is the activation of pro-survival signaling pathways such as PI3K/Akt. LEMD1 overexpression activates the PI3K/Akt cascade in cancer cells (4), which is notable because PI3K/Akt signaling confers broad chemoresistance by upregulating antiapoptotic effectors (such as Bcl-2 and X-linked inhibitor of apoptosis protein) and suppressing proapoptotic factors (such as Bax) (47). Consistently, LEMD1 knockdown sensitizes tumor cells to paclitaxel. For example, in vitro, silencing LEMD1 in paclitaxel-treated MDA-MB-231 TNBC cells downregulates Bcl-2 and increases Bax expression levels, which enhances apoptosis and chemosensitivity, compared with those with paclitaxel treatment alone (11).

Another mechanism is through inducing the EMT and enriching cancer stem-like properties, which are well-known inducers of drug resistance. LEMD1 silencing increases E-cadherin and decreases N-cadherin/vimentin (mesenchymal markers) (11), indicating that LEMD1 normally promotes a mesenchymal, migratory cell state. This shift is notable as the EMT not only facilitates invasion but also often coincides with the upregulation of drug efflux transporters, such as ATP-binding cassette (ABC) sub-family B member 1/P-glycoprotein (multidrug resistance protein 1), ABC sub-family C member 1/multidrug resistance-associated protein 1 and ABC sub-family G member 2/breast cancer resistance protein (48-50), as well as other adaptive mechanisms, including enhanced resistance to apoptosis, increased DNA damage repair capacity and acquisition of cancer stem cell-like properties (51-53), that allow cells to evade chemotherapeutics (54). In addition, the EMT is frequently linked to the emergence of cancer stem-like cells, which is a subpopulation of tumor cells that are intrinsically more chemo-resistant, partly due to their quiescent nature and ability to survive drug-induced stress (54). By supporting a mesenchymal phenotype and potentially maintaining a pool of stem-like cells, LEMD1 endows tumor cells with a capacity to withstand chemotherapy, which may explain why LEMD1-enhanced stemness in NSCLC leads to more stubborn tumors that are difficult to eliminate (28). In summary, high LEMD1 expression levels can protect cancer cells from chemotherapy-induced apoptosis (via survival pathways such as PI3K/Akt) while promoting cellular traits (such as the EMT and stemness) that undermine drug efficacy. Clinically, this suggests that tumors with elevated LEMD1 expression levels may be predisposed to chemoresistance, and conversely that targeting LEMD1 or its downstream signals may help overcome resistance and improve the response to treatment (11).

Therefore, it can be hypothesized that inhibiting LEMD1 in tumors may synergistically enhance the efficacy of conventional treatments. Although current direct research on LEMD1 and drug resistance is limited, the aforementioned indications suggest its potential importance. Future research is needed to further investigate the effects of LEMD1 on the sensitivity to various treatments (such as chemotherapy, targeted drugs and radiotherapy) in different tumor contexts. If the resistance spectrum corresponding to high LEMD1 expression levels can be clarified, it may help formulate more optimized personalized treatment plans.

Despite notable progress in research on LEMD1 in tumors, there are still a number of shortcomings and challenges to overcome. Current basic research on the molecular biological functions of LEMD1 is not in depth enough, with the majority of studies focusing on observing the effects of LEMD1 up- or downregulation on tumor phenotypes and signaling pathways, lacking direct evidence for its specific role in nuclear structure and gene regulation as a nuclear inner membrane protein. For example, it is still unclear whether LEMD1 reshapes chromatin structure through interactions with BAF or nuclear lamina proteins to affect gene expression levels. There are also challenges regarding the ‘druggability’ of LEMD1 as a drug target. Since LEMD1 has no enzymatic active site and is located on the inner nuclear membrane, the use of traditional small molecule drugs to directly target it is difficult. Therefore, innovative drug delivery systems or new types of molecules are needed to achieve effective intervention.

The heterogeneity of LEMD1 expression levels and the functional differences across different types of tumor are yet to be fully elucidated. Although the majority of studies consistently suggest the cancer-promoting effects of LEMD1, there may be exceptions in certain types of cancer. For example, in multiple myeloma, a large-scale study involving 2,546 patients identifies LEMD1 as a favorable prognostic marker in which patients with high LEMD1 expression levels exhibit notably prolonged survival compared with those with low expression (55). In prostatic adenocarcinoma, LEMD1 is frequently upregulated in tumor tissues; however, a comprehensive study failed to demonstrate a notable prognostic impact of LEMD1 in prostate cancer (unlike other LEM family proteins associated with clinical outcomes) (6). By contrast, in ovarian cancer, elevated LEMD1 expression levels are associated with improved patient survival. An integrative genomics study reveals that patients with ovarian tumors and high LEMD1 expression levels have a markedly longer OS compared with the low-expression level group (55,56). This outlier implies that the oncogenic role of LEMD1 is not universal and might be modulated by tissue-specific contexts. One hypothesis is that the immune microenvironment in ovarian cancer may respond uniquely to LEMD1. As an immunogenic CTA, high LEMD1 expression levels in ovarian tumors might stimulate stronger anti-tumor immune responses, making the tumor more immunologically ‘hot’ and contributing to improved patient outcomes (57,58). In support of this, a number of CTAs are associated with an inflamed tumor microenvironment and favorable clinical outcomes in specific types of cancer. For example, NY-ESO-1 expression levels in TNBC are linked to higher tumor-infiltrating lymphocyte levels, favorable disease-free survival and higher CD8⁺ T-cell counts; Hemogen expression levels in lung adenocarcinoma are associated with CD8⁺ T-cell infiltration and an improved prognosis; and CTA-high seminomas, including preferentially expressed antigen in melanoma-enriched tumors, demonstrate activated T-cell infiltration, with CTA and CD8⁺/regulatory T-cell signatures correlating with recurrence-free survival (57,59-62). Alternatively, ovarian tumors might harbor unique co-factors or signaling contexts (such as hormone-related factors or distinct co-regulated pathways) that alter the downstream effects of LEMD1. In gynecological cells, LEMD1 may interact with tissue-specific partners or regulatory networks, potentially dampening its tumor-promoting activities or even associating its high expression levels with a more differentiated, less aggressive tumor phenotype. In summary, LEMD1 may serve different biological roles in ovarian cancer compared with other malignancies, highlighting the importance of context-dependent research into its functions. Furthermore, immunotherapy targeting LEMD1 is yet to be clinically implemented, and its feasibility and safety are yet to be verified. Additionally, as a member of the CTA family, the potential immunogenicity of LEMD1 is both an advantage and a challenge as it may promote the immune clearance of tumors but it might also be limited by tumor immune evasion mechanisms or even trigger autoimmune responses. Therefore, all of these issues require further investigation.

To address the aforementioned shortcomings, several directions may be worth investigating in the future. At the fundamental level, the molecular mechanism of LEMD1 should be analyzed in depth. Proteomics and biochemical methods could be used to identify LEMD1-interacting proteins and clarify whether they directly bind BAF, chromatin or nuclear lamina components. Techniques such as chromatin immunoprecipitation sequencing could be used to identify genomic regions affected by LEMD1 and investigate its regulatory role in genome-wide transcription and epigenetic modifications. This may possibly reveal the fundamental mechanisms of the cancer-promoting effects of LEMD1. Additionally, the function of LEMD1 should be further evaluated in cellular and animal models. For example, LEMD1 gene knockout mouse models could potentially be constructed to observe possible phenotypic changes in normal development and tumor susceptibility, in order to determine whether LEMD1 is a necessary factor for tumorigenesis.

Furthermore, larger-scale correlation studies should be conducted in clinical samples. This includes detecting LEMD1 expression profiles in different types of cancer and at different stages, combined with patient treatment and survival data, to assess the reliability and independence of LEMD1 as a prognostic or predictive marker. Investigating LEMD1-related immunotherapy should also be advanced. For example, by identifying the T cell epitopes of LEMD1, the presence of natural anti-LEMD1 immune responses in the peripheral blood of patients with cancer could be evaluated. Once its immunogenicity is proven, attempts can be made to develop LEMD1 vaccines or CAR-T cells, testing their anti-tumor effects in animal models. Through these multi-faceted research efforts, a foundation will be laid for LEMD1 to progress from laboratory to clinical application.